title: Consequences of nucleic acid conformation on the binding of a trinuclear platinum drug.
abstract: BBR3464, a charged trinuclear platinum compound, is the first representative of a new class of anticancer drugs to enter phase I clinical trials. The structure of BBR3464 is characterized by two [trans-PtCl(NH(3))(2)] units linked by a tetraamine [trans-Pt(NH(3))(2)¿H(2)N(CH(2))(6)NH(2)¿(2)] unit. The +4 charge of BBR3464 and the separation of the platinating units indicate that the mode of DNA binding will be distinctly different from those of classical mononuclear drugs such as cisplatin, cis-[PtCl(2)(NH(3))(2)]. The reaction of BBR3464 with three different nucleic acid conformations was assessed by gel electrophoresis. Comparison of single-stranded DNA, RNA, and double-stranded DNA indicated that the reaction of BBR3464 with single-stranded DNA and RNA was faster than that with duplex DNA, and produced more drug-DNA and drug-RNA adducts. Electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry was used to further characterize the binding modes of BBR3464 with the DNA substrates. BBR3464 binding to different nucleic acid conformations raises the possibility that the adducts of single-stranded DNA and RNA may play a role in the different antitumor efficacies of this novel drug as compared with cisplatin.
authors.affiliation: Department of Chemistry, Department of Biochemistry and Molecular Biophysics, and The Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23284-2006, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: Kloster
authors.forename: J C
authors.initials: JC
authors.lastname: Hannis
authors.forename: D C
authors.initials: DC
authors.lastname: Muddiman
authors.forename: N
authors.initials: N
authors.lastname: Farrell
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism*; D004247:DNA / Q000378:metabolism*; D004277:DNA, Single-Stranded / Q000378:metabolism; D013058:Mass Spectrometry; D009690:Nucleic Acid Conformation; D009944:Organoplatinum Compounds / Q000378:metabolism*; D012313:RNA / Q000378:metabolism*; D017550:Spectroscopy, Fourier Transform Infrared; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D004277:DNA, Single-Stranded; D009944:Organoplatinum Compounds; D012313:RNA; D004247:DNA; C114062:BBR 3464